emibetuzumab + ramucirumab

The combination of emibetuzumab + ramucirumab is a targeted therapy approach that combines two monoclonal antibodies with distinct mechanisms of action. This combination has been studied in clinical trials for various advanced cancers, particularly focusing on tumors where both MET and VEGFR-2 pathways may play important roles in tumor growth and progression. ## Mechanism of Action Emibetuzumab (also known as LY2875358) is a monoclonal antibody that targets the MET receptor (hepatocyte growth factor receptor). MET activation is associated with tumor growth, invasion, and metastasis in various cancers. By inhibiting MET signaling, emibetuzumab aims to block these cancer-promoting effects[1]. Ramucirumab (also known as LY3009806 or IMC-1121B) is a monoclonal antibody that targets VEGFR-2 (vascular endothelial growth factor receptor 2). By blocking VEGFR-2, ramucirumab inhibits angiogenesis (the formation of new blood vessels), which is crucial for tumor growth and metastasis[1][4]. The rationale behind combining these agents is that cancers may evade the anti-angiogenic effects of VEGFR-2 inhibition through activation of the MET pathway. By targeting both pathways simultaneously, the combination therapy aims to provide more comprehensive inhibition of tumor growth mechanisms[1]. ## Clinical Development The combination has been studied in a Phase 1b/2 clinical trial (NCT02082210) that evaluated its safety and efficacy in patients with advanced cancers[2][4]. The study had two parts: - Part A: A dose-escalation phase to determine the recommended dosing schedule - Part B: Expansion cohorts in specific tumor types to evaluate efficacy and confirm safety[2][4] The study enrolled patients with various solid tumors, including: - Gastric or gastroesophageal junction adenocarcinoma - Hepatocellular carcinoma (HCC) - Renal cell carcinoma - Non-small cell lung cancer[1] ## Clinical Results The Phase 1b/2 study enrolled a total of 97 patients across different tumor types. Key findings included: - Safety: The combination was generally well-tolerated with mostly mild to moderate adverse events. Common side effects included fatigue (36.1%), peripheral edema (28.9%), and nausea (14.4%). No dose-limiting toxicities were observed[1]. - Efficacy: The combination showed modest antitumor activity with 5 partial responses (5.2%) observed across all tumor types. The greatest activity was noted in hepatocellular carcinoma with: - 6.7% overall response rate - 60% disease control rate - 5.42 months progression-free survival[1] - Biomarkers: Patients with HCC and high MET expression showed improved progression-free survival (8.1 vs. 2.8 months) compared to those with low MET expression, suggesting MET expression may help select patients who would benefit most from this combination[1]. The study concluded that ramucirumab plus emibetuzumab demonstrated safety and exhibited cytostatic antitumor activity, with MET expression potentially serving as a biomarker to identify patients who might benefit most from this combination treatment in select tumor types[1].